David Ricks, Eli Lilly CEO (Al Drago/Bloomberg via Getty Images)
Lilly to build manufacturing capacity at risk to prepare for next-gen oral obesity drug
Eli Lilly is stuck in a hard place — it’s got the capital to spend to boost manufacturing capacity. But the complexity of building, buying and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
